AIM
TEVA icon

Achmea Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Achmea Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-403,824
Closed -$8.16M – 288
2025
Q3 		$8.16M Sell
403,824
-277,863
-41% -$4.88M 0.1% 179
2025
Q2 		$11.4M Sell
681,687
-56,698
-8% -$915K 0.15% 164
2025
Q1 		$11.3M Sell
738,385
-122,509
-14% -$2.19M 0.17% 153
2024
Q4 		$19M Buy
860,894
+286,371
+50% +$5.21M 0.31% 77
2024
Q3 		$10.4M Sell
574,523
-12,665
-2% -$222K 0.17% 151
2024
Q2 		$9.54M Buy
587,188
+26,051
+5% +$401K 0.17% 146
2024
Q1 		$7.92M Hold
561,137
– – 0.15% 162
2023
Q4 		$5.86M Buy
561,137
+250,413
+81% +$2.34M 0.12% 195
2023
Q3 		$3.17M Buy
310,724
+101,702
+49% +$947K 0.07% 267
2023
Q2 		$1.57M Buy
209,022
+107,097
+105% +$868K 0.03% 372
2023
Q1 		$902K Buy
101,925
+15,857
+18% +$157K 0.03% 402
2022
Q4 		$735K Buy
86,068
+12,816
+17% +$112K 0.02% 440
2022
Q3 		$591K Hold
73,252
– – 0.02% 464
2022
Q2 		$551K Hold
73,252
– – 0.02% 479
2022
Q1 		$688K Buy
+73,252
New +$611K 0.02% 497
2021
Q1 		– Sell
-263,146
Closed -$2.54M – 513
2020
Q4 		$2.54M Buy
263,146
+29,438
+13% +$282K 0.09% 267
2020
Q3 		$2.11M Buy
+233,708
New +$2.47M 0.09% 257
2020
Q1 		– Sell
-57,044
Closed -$559K – 523
2019
Q4 		$559K Buy
+57,044
New +$509K 0.02% 437
2019
Q3 		– Sell
-121,752
Closed -$1.12M – 521
2019
Q2 		$1.12M Sell
121,752
-30,380
-20% -$366K 0.04% 366
2019
Q1 		$2.39M Buy
152,132
+15,613
+11% +$275K 0.1% 221
2018
Q4 		$2.11M Buy
136,519
+88,405
+184% +$1.81M 0.1% 221
2018
Q3 		$1.04M Hold
48,114
– – 0.04% 361
2018
Q2 		$1.17M Hold
48,114
– – 0.04% 346
2018
Q1 		$822K Hold
48,114
– – 0.03% 401
2017
Q4 		$911K Buy
48,114
+26,680
+124% +$401K 0.03% 388
2017
Q3 		$377K Hold
21,434
– – 0.02% 425
2017
Q2 		$712K Hold
21,434
– – 0.04% 368
2017
Q1 		$688K Buy
+21,434
New +$731K 0.03% 409

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Achmea Investment Management's TEVA Position: Q4 2025 in Review

Achmea Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 403,824 shares — an estimated $8.16M sold.

Achmea Investment Management first reported a position in TEVA in Q1 2017 and held it in 28 quarters. The position peaked at $19M in Q4 2024. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Achmea Investment Management reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Achmea Investment Management sold 403,824 Teva Pharmaceuticals shares in Q4 2025, an estimated $8.16M.
  • Achmea Investment Management first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 28 quarters.
  • Achmea Investment Management's Teva Pharmaceuticals position peaked at $19M in Q4 2024.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Achmea Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.